1YBelow half the group
Rank 163 of 224 funds
Return −2.06%
1Y returns of 224 funds in the Global Equity group, sorted from highest to lowest. This fund ranks 163No. 1 is I-10 +51.44%
ONE DISCOVERY FUND
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
ONE-DISC-RA invests through the master fund Baillie Gifford Worldwide Discovery Fund 100.33%
This fundONE-DISC-RA
The fund that actually investsBaillie Gifford Worldwide Discovery FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Twist Bioscience TWST5.92%
Xometry XMTR4.82%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Baillie Gifford fact sheet
Over the past year it trailed half its group; over 5 years it returned −13.24% per year (Bottom 25% of the group)
No. 1 is I-10 +51.44%
Each bar is one fund in the AIMC Global Equity group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|---|
| +3.44% | −3.62% | −2.36% | −10.66% | +0.21% | +5.78% | −2.06% | +26.63% | −50.84% | −18.89% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan |
|---|
Largest drawdown in the selected period −74.39% Previous peak 16 Feb 2021 (NAV 21.8866) → Trough 9 Apr 2025 (NAV 5.6041) · Not back to the previous peak as of 3 Nov 2026
Currently −62.94% from the peak NAV of 21.8866 (16 Feb 2021)
Over 5 years, ONE-DISC-RA returned -0.44 per unit of volatility, ranking 85 of 86 funds · The highest is UGEAR (1.68)
รายละเอียดเพิ่มเติม :กองทุนมีนโยบายลงทุนในหน่วยลงทุนของกองทุนต่างประเทศเพียงกองทุนเดียว (Master Fund) คือ กองทุน Baillie Gifford Worldwide Discovery Fund (กองทุนหลัก) ในหน่วยลงทุนชนิด Class B USD Accumulation (ชนิด B สกุลเงิน USD ประเภทสะสมมูลค่า) โดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80… Its largest holdings are Twist Bioscience 5.90% · Xometry, Inc 4.80% · Alnylam Pharmaceuticals 4.10% (fact sheet 30 Sep 2026)
Risk level 6 of 8 (High risk). Since 20 Nov 2019, its NAV has fallen as much as −74.39% from its peak.
Actual total expense ratio (TER) 1.90% a year, against a ceiling of 5.28%. Management fee 1.61%. Front-end fee 1.50%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 5,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 81.18% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · ONE-DISC-RA: no dividends, TER 1.90% · ONE-DISC-ASSF: no dividends, TER 1.80% · ONE-DISC-DSSF: see the conditions in the prospectus · ONE-DISC-IA: see the conditions in the prospectus · ONE-DISC-ID: see the conditions in the prospectus · ONE-DISC-RD: see the conditions in the prospectus
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Alnylam Pharmaceuticals ALNY4.11%
Oxford Nanopore Tech ONT3.91%
Astera Labs ALAB3.71%
Axon Enterprise AXON3.31%
Guardant Health GH3.21%
MercadoLibre MELI2.81%
Revolution Medicines RVMD2.61%Twist Bioscience TWSTMakes synthetic DNA on silicon chips for drug and genetics research
Xometry XMTRHospitals, medicines and medical equipment
Mobile networks, internet and software
Astera Labs ALABAxon Enterprise AXONHospitals, medicines and medical equipment
MercadoLibre MELILatin American online shopping platform with the Mercado Pago payment service
Revolution Medicines RVMDBiotech company that develops drugs for RAS-driven cancers, such as pancreatic cancer
Based on the master fund's share of this fund's value (100.33% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Baillie Gifford · Illustrations are for explanation only, not individual stock recommendations
No. 1 is ES-GINNORMF +19.21% per year
No. 1 is K-GLOBE +9.72% per year
| Feb |
|---|
| Mar |
|---|
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +2.4 | −4.2 | −14.7 | +16.8 | +19.1 | −2.0 | −9.6 | +10.0 | +1.7 | −4.9 | −5.8 | · | +3.4* |
| 2025 | +3.2 | −10.2 | −5.5 | +1.4 | +7.2 | +7.0 | +3.9 | +5.2 | +1.6 | −0.3 | −4.9 | +0.6 | +7.8 |
| 2024 | −8.6 | −1.3 | −0.1 | −5.6 | −1.0 | +3.5 | +3.7 | +0.3 | +1.7 | +0.5 | +6.0 | −5.3 | −7.0 |
| 2023 | +10.3 | −7.3 | −1.7 | −2.5 | −1.9 | +3.6 | +6.8 | −7.6 | −11.8 | −11.2 | +13.5 | +12.3 | −1.8 |
| 2022 | −19.6 | +1.4 | +3.4 | −17.1 | −5.7 | −7.8 | +3.3 | +3.3 | −11.2 | −1.2 | +2.7 | −2.7 | −43.2 |